Company intelligence / Profile preview

Polifarma

Ownership: Private
Employees: ~160
Development stage: Commercial

Overview

Polifarma operates as a commercial-stage pharmaceutical company with a broad portfolio of hospital and prescription products across several therapeutic areas including CNS, cardiovascular, gastroenterology, ophthalmology and infectious disease. The Turkish entity is a leading producer of parenteral solutions and injectables for hospitals with significant manufacturing capacity.[1][2][3][4]

Therapeutic areas: GastroenterologyCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculesParenteral solutions (IV infusions, injectables)
Industry: Biotech

Drug pipeline

1 asset

Polifleks Isolen-S

Unknown

Partnerships

Italy – Ophthalmic area partnership with historical market company[1]Turkey – No major partnerships disclosed

Beyond the preview

Go deeper on Polifarma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polifarma.

Explore the full profile